<DOC>
<DOCNO>EP-0611375</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PEPTIDES INHIBITING IL-1 BETA RELEASE.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3800	A61K3800	A61P4300	A61P4300	C07K100	C07K1113	C07K500	C07K502	C07K506	C07K5078	C07K5083	C07K700	C07K706	C07K14435	C07K14545	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	C07K	C07K	C07K	C07K	C07K	C07K	C07K	C07K	C07K	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	A61K38	A61P43	A61P43	C07K1	C07K1	C07K5	C07K5	C07K5	C07K5	C07K5	C07K7	C07K7	C07K14	C07K14	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Di-, tri- and tetrapeptides in which the last  alpha -amino acid is based on aspartic acid and attached to a residue A5 which is H; CF3; -Z1-Z2-Y2 wherein each of Z1 and Z2 independently is a direct bond or an  alpha -amino acid residue and Y2 is NH2, C1-4 alkylamino, di-(C1-4 alkyl)amino or a heterocyclic radical attached by a nitrogen to Z2; -CH2-X1-Y3 wherein X1 is O or S and Y3 is heteroaryl; -CH2-Y3; substituted phenyl; ring substituted phenoxymethylene or phenylthiomethylene; ring substituted pyridyloxymethylene; or a radical -CH2-X1-CO-Y4 wherein X1 is O or S and Y4 is trialkylmethyl or substituted phenyl or pyridyl, in free form or in salt form, have pharmacological activity, e.g. IL-1 beta  release inhibiting properties.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SANDOZ AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ LTD
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ LTD.
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ-PATENT-GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HENG RICHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
PAYNE TREVOR GLYN
</INVENTOR-NAME>
<INVENTOR-NAME>
REVESZ LASZLO
</INVENTOR-NAME>
<INVENTOR-NAME>
WEIDMANN BEAT
</INVENTOR-NAME>
<INVENTOR-NAME>
HENG, RICHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
PAYNE, TREVOR, GLYN
</INVENTOR-NAME>
<INVENTOR-NAME>
REVESZ, LASZLO
</INVENTOR-NAME>
<INVENTOR-NAME>
WEIDMANN, BEAT
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 PEPTIDES INHIBITING IL-1 BETA RELEASEThe present invention relates to peptides having pharmaceutical utility, processes for their production, pharmaceutical compo¬ sitions comprising them and their use as pharmaceuticals.More particularly the present invention provides a compound of formula IR-[A1-A2]n-A3-A4-X-A5 (I)whereinR is hydrogen, an amino protecting group or optionally ring substituted benzyloxy Ax is Val, Leu, Ala, lie or trimethylsilyl-Ala A2 is Phe or Tyr, n is 0 or 1, A3 is a direct bond, Val, Leu, Ala, lie, trimethylsilyl-Ala or a divalent radical of formula (a)vherein ring A is optionally substituted by hydroxy or Cι_4alkoxy, 

 is a direct bond or a divalent radical of formula (b)-N - CH-C0-I I (b) Rx iwherein Rj. is hydrogen or C^^alkyl, andYi is the residue attaching to the α-carbon atom of an α-amino acid and optionally protected, -CH2-CH2-N(Cι_4alkyl)2, imidazol-2-yl-methyl, benzimidazol-2-yl-methyl, 1H-1,2,4-triazol-3-yl- methyl, pyrazol-3-yl-methyl, indazol-3-yl-methyl or a radical of formula (c) or (d)(c) (d).wherein each of R2 and R3, independently, is hydrogen, halogen, C!_4alkyl, CF3 or trityl, at most one of R2 and R3 being H, and each of R4 and R5 independently is hydrogen,Cι_ alkyl, hydroxy, C1_4alkoxy, CF3, phenyl or halogen, at most one of R4 and R5 being H, or A3 and A4 form together a radical of formula (aa)-NH-CH - CO-N - CH-C0-I I I (aa) R-la Ri Yi wherein Yi is as defined above and Rx and Ria form together -(CH2)m- wherein m is 2, 3, 4 or 5, and 

1) X is a divalent radical of formula (ei)
 wherein R6 is H or Cι_4alkyl, and A5 is hydrogen; CF3 ; a radical -Z1-Z2-Y2 wherein each of Zx and Z2 independently is a direct bond or an α-amino acid residue and Y2 is NH2 , Ci-4alkylamino, di-(Cι_4al- kyl)amino or a heterocyclic radical attached by a nitro¬ gen to Z2 ; a radical -CH2-Xi-Y3 wherein Xj. is 0 or S and Y3 is heteroaryl; a radical -CH2-Y3; or a radical of formulae (k) to (m)(k) (1)whereinY4 is tri-(Cι_4alkyl)methyl orring B is pyridyl, 

 ring C is phenyl or pyridyl, each of R7 and R8 independently is C _.ialkyl, 
CF3 , halogen, nitro or cyano, and each of R9, κ> and Rn independently is nitro, cyano,CF3, carbamoyl, C02R12, -CH=CH-CN or -CH=CHC02R12 whereinR12 is Cι_6alkyl,X being also a divalent radical of" formula (e2)when A5 is H, or2) X is a divalent radical of formula (f ) ,
 and A5 is -Z1-Z2-Y2 or a radical of formulae (k) to (o) as defined above, or OR13 or R14R15 wherein R13 is C!_ι2 l¬ kyl optionally substituted by OH or interrupted by 0 and each of Ri4 and
</DESCRIPTION>
<CLAIMS>
CLAIM
1. A compound of formula I
R-[A
1
-A
2
_I
n
-A
3
-A
4
-X-A
5
 (I)
wherein
R is hydrogen, an amino protecting group or optionally ring substituted benzyloxy n is 0 or 1,
Ai is Val, Leu, Ala, lie or trimethylsilyl-Ala A
2
 is Phe or Tyr, A
3
 is a direct bond, Val, Leu, Ala, lie, trimethylsilyl-Ala or a divalent radical of formula (a)

 wherein ring A is optionally substituted by hydroxy or
C
x
_
4
alkoxy,
A
4
 is a direct bond or a divalent radical of formula (b)
-N - CH-CO- ! I (b)
Hi ϊi
wherein i is hydrogen or Cι_
4
alkyl, and 
x
 is the residue attaching to the α-carbon atom of an α-amino acid and optionally protected, -CH
2
-CH
2
-N(Cι_
4
alkyl)2, imidazol-2-yl-methyl, benzimidazol-2-yl-methyl, lH-l,2,4-triazol-3-yl- methyl, pyrazol-3-yl-methyl, indazol-3-yl-methyl or a radical of formula (c) or (d) 

wherein each of R
2
 and R
3
 , independently, is hydrogen, halogen, Cι_
4
alkyl, CF
3
 or trityl, at most one of R
2
 and R
3
 being H, and each of R
4
 and R
5
 independently is hydrogen,
Ci...,
!
alkyl, hydroxy, Cι_
4
alkoxy, CF
3
 , phenyl or halogen, at most one of R
4
 and R
5
 being H, or A
3
 and A
4
 form together a radical of formula (aa)
-NH-CH CO-N - CH-C0-
I I I (aa) Ri. Ri i wherein Yi is as defined above and Ri and R
ia
 form toge¬ ther -(CH
2
)
a
- wherein m is 2, 3, 4 or 5, and i) X is a divalent radical of formula (ei)

 wherein R
6
 is H or Cι_
4
alkyl, and A
5
 is hydrogen; CF
3
 ; a radical -Z
x
-Z
2
-Y
2
 wherein each of Z
x
 and Z
2
 independently is a direct bond or an α-amino acid residue and Y
2
 is NH
2
 , Cι_
4
alkylamino, di-(Cι_
4
_ alkyl)amino or a heterocyclic radical attached by a 


 nitrogen to Z
2
; a radical -CH
2
-Xι-Y
3
 wherein Xj. is 0 or S and Y
3
 is heteroaryl; a radical -CH
2
-Y
3
; or a radical of formulae (k.) to (m)
wherein
Y
4
 is tri-(Cι_
4
alkyl)methyl or a residue
ring B is pyridyl, 


 ring C is phenyl or pyridyl, each of R
7
 and R
8
 independently is Cι_
4
alkyl,
Cι_
4
alkoxy, CF
3
, halogen, nitro or cyano, and each of R
9
 , Rio and R
u
 independently is nitro, cyano,
CF
3
, carbamoyl, C0
2
R
i2
, -CH.CH-CN or -CH=CHC0
2
R
12
 wherein R
i2
 is Cι_
6
alkyl,
being also a divalent radical of formula (e
2
) 


 vl
kyl (e
2
)
y 1
when A
5
 is H, or ii) X is a divalent radical of formula (f),
and A
5
 is -Z
!
-Z
2
-Y
2
 or a radical of formulae (k) to (0) as defined above, or 0R
13
 or NR
14
R
15
 wherein R
13
 is Cι_
1
 alkyl optionally substituted by OH or interrupted by 0 and each of R
i4
 and R
15
 is independently hydrogen, Cι_ι
2
alkyl, C
5
_
7
cycloalkyl or benzyl, or iii)X is a divalent radical of formula (g)
and A
5
 is -Zι-Z
2
-Y
2
 as defined above, or iv) X is a divalent radical of formula (h) or (j) 

(h) (j )
and A
5
 is a radical of formulae (k) to (o), -CH
2
-Y
3
 or __ -CH
2
-Xι-Y
3
 as defined above,
with the provisos that only one of A
3
 and A
4
 can be a direct bond when n is 0, and each of A
3
 and A
4
 is other than a direct bond when n is 1.
and the physiologically-hydrolysable and -acceptable esters or amides thereof,
in free form, in salt form or in the form of complexes.
2. A compound of formula I according to claim 1, wherein n is 0, A
3
 is a direct bond, Val, Leu, Ala, lie or trime¬ thylsilyl-Ala, A
4
 is as defined in claim 1, or A
3
 and A form together a radical of formula (aa) as defined in claim 1, and i) X is a radical of formula (ei) or (e
2
) as defined in claim 1 and A
5
 is H, or ii) X is a radical of formula (ei) or (f) and A
5
 is
-Z
!
-Z
2
-Y
2
 as defined in claim 1 or a radical of formula
(k), (1) or (m) as defined in claim 1 wherein X
x
 is 0, iii)X is a radical of formula (g) and A
5
 is -Zι-Z
2
-Y
2
 as defined in claim 1, or iv) X is a radical of formula (j) and A
5
 is a radical of formula (k), (1) or (m) as defined in claim 1 wherein Xi is 0. 


 and the physiologically-hydrolysable and -acceptable esters or amides thereof, in free form, in salt form or in the form of complexes.
3. A compound of formula I according to claim 1 wherein n is 0 and each of A
3
 and A
4
 are other than a direct bond, and the physiologically-hydrolysable and -acceptable esters or amides thereof, in free form, in salt form or in the form of complexes.
4. A compound of formula I according to claim 1 or 3 wherein Yi is the residue attaching to the α-carbon atom of an α-amino acid selected from Ala, Leu, His, Phe, Met, Trp, trimethyl¬ silyl-Ala and optionally side chain protected Arg, Orn and Lys, or a radical of formula (c), and the physiologically- hydrolysable and -acceptable esters or amides thereof, in free form, in salt form or in the form of complexes.
5. A compound of formula I according to claim 1, 3 or 4 wherein X is a radical of formula (ei), (h) or (j), A
5
 being other than H when X is (ei), and the physiologically-hydrolysable and -acceptable esters or amides thereof, in free form, in salt form or in the form of complexes.
6. (Benzyloxycarbonyl-valyl-alanyl)-3R-3-amino~4-oxo-5-(2,6-di chlorobenzoyloxy) pentanoic acid ethyl ester, (benzyloxy- carbonyl-valyl-alanyl)-3R,S-3-amino-4-oxo-5-(2,6-dichloro benzoyloxy) pentanoic acid ethyl ester, (benzyloxycarbo- nyl-valyl-alanyl)-3R-3-amino-4-oxo-5-(2,6-dichloro-pyridyl-4- carbonyloxy) pentanoic acid ethyl ester, (benzyloxycarbo- nyl-valyl-alanyl)-3R,S-3-amino-4-oxo-5-(2,6-dichlorobenzoyl oxy) pentanoic acid, (benzyloxycarbonyl-valyl-alanyl)-3R,S- 3-amino-4-oxo-5-(2,6-dichlorobenzoyloxy) pentanoic acid isopropyl ester, (benzyloxycarbonyl-valyl-alanyl)-3R,S-3- 


 amino-4-oxo-5-(2,6-dichlorobenzoyloxy) pentanoic acid t.-butyl ester, and (benzyloxycarbonyl-valyl-alanyl)-3S- -3-amino-4-oxo-5-(2,6-dichlorobenzoyloxy) pentanoic acid in free form, in salt form or in the form of complexes.
A process for producing a compound of formula I and the phy¬ siologically-hydrolysable and -acceptable esters and amides thereof, as defined in claim 1, which process comprises
a) removing at least one protecting group from a compound of formula I in protected form or adding a protecting group R as defined in claim 1 at the N-terminal group of a compound of formula I; or
b) converting one compound of formula I into another compound of formula I; or
c) coupling together by an amide bond two peptide fragments, each of which contains at least one amino acid in protec¬ ted or unprotected form and one peptide fragment contai¬ ning a radical of formula ei) to (j) as defined in claim 1, the peptide fragments being such that a protected or unprotected peptide having the sequence according to for¬ mula I above is obtained and, if necessary, removing the protecting group or groups from a compound of formula I in protected form; or
d) for the production of a compound of formula I wherein X is a radical of formula (ei) or (h) and A
5
 is a radical of formula (k), (1) or (o) or -CH
2
-Xι-Y
3
 as defined in claim 1, reacting a compound of formula III
R-[A
!
-A
2
]
n
-A
3
-A
4
-X'-CH
2
-Z
a
 (III) 


 wherein R, A
x
 to A
4
 and n are as defined in claim 1, X' is a radical of formula (ei) or (h) as defined in claim 1, and Z
a
 is a leaving group, with a corresponding phenol, thiophenol or H 
X
-pyridine or an acid of formula HXι-C0-Y
4
 or a functional derivative thereof or HXχ-Y
3
 wherein X
x
 , Y
3
 and Y
4
 are as defined in claim 1; or
e) for the production of a compound of formula I
wherein R, Ai to A
5
 and n are as defined in claim 1 and Rie is a Cι_ι
2
 aliphatic or alicyclic residue, oxidizing a compound of formula V
wherein R, Ai to A
5
, n and Rι
6
 are as defined above,
and recovering a compound of formula I or a physiologically- hydrolysable and -acceptable ester or amide thereof thus obtained in free or salt form or in the form of a complex.
8. A compound according to any one of claims 1 to 6 for use as a pharmaceutical.
9. A pharmaceutical composition comprising a compound of formula 


 I as defined in claim 1 or a physiologically-hydrolysable and -acceptable ester or amide thereof, in free form or in phy¬ siologically acceptable salt form, together with a pharmaceu¬ tically acceptable diluent or carrier therefor.
10. A method for the treatment of disorders with an aetiology associated with or comprising excessive IL-lβ release, in a subject in need thereof, which method comprises administering to said subject an effective amount of a compound of formula I as defined in claim 1, a physiologically-hydrolysable and -acceptable ester or amide thereof, or a pharmaceutically acceptable salt thereof. 

</CLAIMS>
</TEXT>
</DOC>
